Despite matching for serologically defined HLA-A, B, DR antigens, acute graft-versus-host disease (GVHD) is a major complication contributing to increased morbidity and mort a l i in patients who undergo marrow transplantation from unrelated donors. The extent to which unrecognized mismatching for alleles that encode DRI-DR18 contribute to the increased risk of acute GVHD and overall survival is unknown. We analyzed 364 patients and their HLA-A, B, DR serologically matched donors to determine whether molecular typing of DRBI alleles can allow more accurate donor/ recipient matching and thereby improve clinical outcome after marrow transplantation. DRBl alleles were typed by sequence-specific oligonucleotide probe hybridization methods. Selected alleles were confirmed by DNA sequencing.
matching for serologic specificities has been supplemented by matching for Dw subtypes identified by testing with homozygous typing cells (HTC) that measure in vitro T-cell responses.' Hence, Dw subtyping has served historically as a secondary definition of class I1 molecular diversity. The HLA-DR locus is now known to encompass a nonpolymorphic DRA gene and several polymorphic DRB genes that include DRB1, DRB3, DRB4, and DRBS. The DRl-DR18 specificities recognized by alloantisera are encoded by DRB1. Recently, DNA amplification methods have made it possible to type the alleles of the DRB 1 gene. These molecular approaches have elucidated the highly polymorphic nature of the HLA system and have defined more than 106 DRB 1 alleles. ' In previous studies of unrelated donor transplantation, the presence of a single mismatch for HLA-A or B or Dw was associated with an increased risk of acute graft-versus-host disease (GVHD).'" Recipients of HLA-A, B, Dw-matched unrelated donor marrow had the lowest risk of acute GVHD, but this risk was still much higher than in HLA-identical sibling transplants. Improved overall survival was not apparent in HLA-A, B, Dw-matched recipients when compared with mismatched recipients, and the effect of HLA matching on survival after unrelated transplantation has remained inconclusive.
Unrecognized or undefined mismatching for DRB 1 genes between the donor and recipient can exist despite matching for HLA-A, B and DR and could contribute to the high risk of acute GVHD after transplantation. We tested this hypothesis in a large transplant population by identifying the DRBl alleles in 364 HLA-A, B, DR serologically matched unrelated transplant pairs and by analyzing the effects of DRBl matching on the risk of acute GVHD. In addition, with a much larger unrelated transplant experience in hand, we examined the association of DRBl allele matching and survival. Our results show that matching for alleles of the DRBl locus reduces the risk of acute GVHD and improves survival after transplantation.
MATERIALS AND METHODS
Histocompatibility typing. Serologic typing for HLA-A and B was performed using the standard two-stage National Institutes of Health complement-dependent microcytotoxicity test. Typing for HLA-DR was performed using Dynabead-purified B cells in a microcytotoxicity assay." Dw phenotypes were determined with the use DNA for molecular typing was extracted from whole blood collected in EDTA, from lymphoblastoid cell lines (LCL) prepared by Epstein-Barr virus transformation, or from purified lymphocyte preparations.'2 All DlU3 1 alleles recognized by the WHO Nomenclature Committee for Factors of the HLA system9 were typed by amplification of the second exon of DRBI followed by sequencespecific oligonucleotide probe (SSOP) hybridization.'* DNA SSOP typing was supplemented by allele-specific sequencing to define all alleles producing novel hybridization patterns. In this analysis, DRBl alleles were determined retrospectively for all individuals whose HLA typing originally lacked this level of resolution. HLA-DRB3, DRB5, DQBl. and DPBl were not evaluated in this study. Because the primary endpoint of this study was the development of acute GVHD, patients were excluded from the analysis if they received GVHD prophylaxis other than methotrexate ( " R ) and cyclosprine (CSP), underwent a prior autologous marrow transplant, failed to engraft, or survived less than 10 days after transplant. Excluded from the analysis were 4 DRB1-matched patients who failed to engraft and a single DRB1-matched patient who died 2 days after the transplant.
The analysis also included 9 donorkecipient pairs who, at the time of the transplant, were matched by serology for DR2, DR5, and DR6. These pairs were more fully characterized in the present study and found to have mismatches between DRB1*15/16, DRB1*11/12, and DRB1*13/ 14, respectively. Because the primary objective in this analysis was to study the clinical outcome of patients typed with the most robust methods available at the time of the transplant, these 9 DR-mismatched patients were not excluded from the analysis. Table 1 summarizes the clinical characteristics of the 364 pairs evaluated in this study.
Dejinition of DRBl mismatch. The presence of a DRBl mismatch was evaluated for each donodrecipient pair by determining whether the mismatch involved patient DRBl alleles not shared by the donor (defined as the GVHD vector) or donor DRBl alleles not shared by the patient (defined as the rejection ~e c t o r ) . '~ Of the 364 transplant pairs evaluated, 59 pairs were DRB1-mismatched for the GVHD vector. Of these, 56 were also mismatched for the rejection vector. None of the 364 pairs had a DRBl mismatch in the rejection vector without a mismatch in the GVHD vector. Hence, a DRBl mismatch was defined as the GVHD vector for all clinical endpoints in this analysis.
Transplantation procedure. All protocols and consent forms used in this study were reviewed and approved by the Institutional Review Board of the Fred Hutchinson Cancer Research Center. Depending on the diagnosis and stage of disease, the pretransplant conditioning regimens included cyclophosphamide (60 mgkg of recipient body weight) administered intravenously on each of 2 successive days followed by total body irradiation (TBI) administered in six fractions of 2.0 Gy, seven fractions of 2.25 Gy, or 11 or 12 fractions of 1.2 Gy from dual opposing 6oCo sources (n = 342). Alternative conditioning regimens included only chemotherapy (n = 22; Table 1 ). Unmodified (T-cell-nondepleted) marrow cells from the unrelated donor were infused intravenously after completion of the conditioning regimen. The number of nucleated cells infused ranged from 1.1 to 11.4 X 108kg of recipient body weight. All patients received MTX and CSP after transplantation for GVHD pro phyla xi^.'^ The transplant characteristics are summarized in Table   1 .
Evaluation of GVHD. The grading of acute GVHD was performed according to standard criteria." The grades were assigned 12 (20) 12 ( For personal use only. on October 22, 2017. by guest www.bloodjournal.org From based on the severity of acute GVHD in the skin, liver, and gastrointestinal tract as follows: none (grade 0), insignificant (grade I), mild (grade II), moderate (grade III), or severe (grade IV).
Statistical considerations. The primary endpoint of thls study was the development of clinically significant (grades III-IV) acute GVHD. Secondary endpoints were relapse, transplant-related mortality, and mortality. Transplant-related mortality is defined as death from any cause other than recurrent malignancy. Conditional probability estimates" were used to display the incidence of acute GVHD. These estimates depict the probability of developing acute GVHD by an indicated time given that relapse, graft rejection, or death without acute GVHD have not occurred by that time. Marginal probability estimates" were used to display the incidence of relapse, where death without relapse was regarded as a competing risk and observations were otherwise censored at the time of last contact. The marginal probability of transplant-related mortality was estimated regarding relapse as a competing risk. Kaplan-Meier estimates were used to display survival probabilities, with censoring at the time of last contact.
The effect of DRB 1 mismatching on the incidence of acute GVHD was evaluated in the context of an age-stratified multivariable Cox proportional hazards regression model.lX Covariables were included to adjust for the potential confounding effects of patient, donor, or treatment characteristics associated with the risk of acute GVHD. A forward stepwise approach was taken in constructing a base model containing the subset of candidate prognostic factors, exclusive of DRB I mismatch, which made the greatest contribution to the model. Factors considered for inclusion in the base model were diagnosis and disease stage at the time of transplant, patient and donor age, patient and donor gender mismatch, donor parity, TB1 exposure and dose, Fluconazole prophylaxis, Ganciclovir prophylaxis, granulocyte-macrophage colony-stimulating factor (GM-CSF) administration, and compliance with MTX and CSP prophylaxis regimens. Only those factors that made the greatest contribution to the model were retained in the base model. The additional effect of DRBl mismatching on the incidence of acute GVHD was then evaluated in the context of this base model.
Associations between DRBl mismatching and relapse, transplantrelated mortality, and survival were examined similarly with regression models constructed for these respective outcomes with the exception that patient age was modeled as a covariable. The P values in the multivariable models correspond to the Wald test of the null hypothesis that the relative risk (RR) is equal to 1.0. P values reported for the association of a DRB 1 mismatch with acute GVHD, relapse, transplant-related mortality, and survival reflect the significance of the Likelihood Ratio Test (LRT) for the additional contribution of DRBl mismatching to the outcome in the respective base models.
The acute GVHD model was stratified on patient age, with one stratum containing patients younger than 36 years of age and the other containing patients who were 36 years of age or older. This stratification was motivated by imbalances for patient age between the DRBI-matched and -mismatched groups that resulted from the donor selection criteria. Patient age was modeled as a covariable in models for transplant-related mortality and survival. This was motivated by the relatively strong estimated contribution of older patient age to transplant-related mortality and survival. Separate hazard estimates were obtained for age categories modeled by decade of life. These estimates suggested a dichotomous representation of patient age, either younger or older than 20 years of age.
RESULTS
HLA compatibility between patients and donors. Among the 364 HLA-A, B, DR serologically identical donodrecipient pairs, 305 were matched and 59 were mismatched for the DRBl alleles. Of the 59 mismatched pairs, 55 were mismatched for one DRB l allele and 4 were mismatched for both DRB 1 alleles. Mismatched alleles were most frequently observed in the DR16 (n = 1/3; 33%), D R l l (n = 20/65; 30%), DR8 (n = 3/13; 23%), DR14 (n = 4/24; 17%), DR4 (n = 18/115; 16%), and DR13 (n = 10/67; 15%) phenotypes and were less frequent in the DR1 (n = 4/80; 5 % ) and DR15 (n = 31109; 3%) phenotypes. Limited statistical power precluded separate analysis of the effect of mismatching for specific DRBl alleles on survival and the development of acute GVHD.
Donor and recipient characteristics. Unrelated donor selection criteria were more stringent for patients older than 36 years of age than those for patients younger than age 36 years of age because of a concern that HLA mismatching in older patients might significantly increase the risk of posttransplant complications." For this reason, DRB l -mismatched patients were younger than DRB 1 -matched patients (Table 1) .
The DRB l-matched and mismatched groups also differed in the distribution of low-, moderate-, and high-risk patients based on diagnosis and disease stage at the time of the transplant. Thirty-five percent of DRBl-matched patients had chronic myelogenous leukemia (CML) in the chronic phase (low risk) compared with 24% of DRBl-mismatched patients; 32% of matched patients were diagnosed with accelerated phase CML, acute leukemia in remission, and aplastic anemia (moderate risk), whereas 40% of DRBl-mismatched patients carried the diagnosis of moderate risk disease. This difference in distribution among diagnostic categories for the matched and mismatched groups probably reflects the relative urgency with which certain patients were transplanted. The slow progression of CML permitted more time to find well-matched donors, whereas the clinical instability of higher-risk patients may have precluded exhaustive searches for well-matched donors before transplantation.
Acute GVHD. The incidence of grades 11-IV acute GVHD was .88 in the matched patients, compared with .96 in mismatched patients.
The risk of grades 111-IV acute GVHD was .48 in the DRBl-matched patients and .70 in the mismatched patients (Fig 1) . Univariate analysis of the association of DRBl mismatching with the development of grades 111-IV acute GVHD yielded an estimated RR of 1.8 (95% confidence interval [CI], 1.2 to 2.6; P = .OM). Multivariate analysis yielded an estimated RR of 1.4 (95% CI, 1.0 to 1.8; P = .06) for grades 11-IV and 1.7 (95% CI, 1.2 to 2.5; P = ,007) for grades 111-IV after accounting for the contribution of disease stage and gender mismatch ( Table  2) .
The DRB l-matched and DRB 1 -mismatched groups were similar with regards to the number of patients who received at least 80% of the specified dose of MTX or CSP out of the total number of patients who were still at risk of developing acute GVHD at the end of the treatment period (days 1, 3, 6, and 11 for MTX; weeks 1, 2, 3, 4, and 5 for CSP; Table 1 ). Including a time-dependent covariable for compliance with MTX and CSP prophylaxis did not change the estimate of the association between DRB 1 mismatching and acute GVHD. Because the DRB1-matched group differed from the DRB l -mismatched group with respect to exposure and dose of TB1 (n = 32, Table l), the association between DRB l-mismatching and acute GVHD was also evaluated by excluding these DRB l-matched patients. The RR estimates were unchanged (RR, 1.7; P = .007 with inclusion of all patients; RR, 1.8; P = .005 excluding the 32 DRBl-matched patients). Results of the multivariable analysis show that the association of DRBl mismatching with increased risk of acute GVHD cannot be explained by imbalances in the risk factors evaluated. Therefore, we conclude that DRB 1 disparity itself is a risk factor for acute GVHD. Relapse, transplant-related mortality, and survival. Overall, 186 (61%) DRBl-matched patients and 43 (73%) DRBl-mismatched patients died. Of the 186 deaths in the matched group, 55 (30%) patients died with relapse and 131 (70%) died without relapse. Six matched patients relapsed but survived. Of the 43 mismatched patients who died, 11 (26%) died with relapse and 32 (74%) died without relapse. The presence of a DRBl match was associated with decreased transplant-related mortality at l year in matched patients (.39; 95% CI, .33 to .44) compared with mismatched patients (S1; 95% CI, .39 to .65; Fig 2) . In keeping with this observation, matched patients had improved survival at 1 year (.48; 95% CI, .42 to .53) compared to mismatched patients (.35; 95% CI, .23 to .47; Fig 3) .
The univariate estimate of the RR was 1.4 (95% CI, 1.0 to 2.0; P = .04) for overall mortality and 1.5 (95% CI, 1.0 to 2.2; P = .04) for transplant-related mortality. In the multivariate analysis, diagnosis, advanced disease stage, and the presence of a gender mismatch were associated with increased overall mortality and transplant-related mortality (Table 3) . With adjustment for the contribution of these factors, the estimated RR of overall mortality among DRBlmismatched patients was 1.4 (95% CI, 1.0 to 2.0; P = .06) compared with matched patients; the estimated RR of transplant-related mortality among DRB 1 -mismatched patients was 1.5 (95% CI, 1.0 to 2.2; P = .04) compared with matched patients. Two-year disease-free survival (DFS) estimates were unchanged because only 6 patients relapsed but survived (.40 survival and .39 DFS in the DRB1-matched group; .29 survival and .28 DFS in the DRBl-mismatched group). In this study, there was no detectable association between DRBl mismatching and risk of relapse (RR, 230; 95% CI, .42 to 1.5; P = S O ; Fig 2) . These results indicate that DRBl mismatching is an independent risk factor for mortality.
Because the primary endpoint of this study was the development of acute GVHD, the patients were deemed inevaluable for acute GVHD and excluded from the analysis if they failed to engraft (n = 4) or died before 10 days after transplant (n = 1). Because all 5 of these patients were DRB1-matched with their donor, we also analyzed overall mortality and transplant-related mortality outcomes with these 5 patients included. The resulting RR estimates for overall mortality (RR, 1.4; 95% CI, 1.0 to 1.9; P = .06) and transplantrelated mortality (RR, 1.5; 95% CI, 1.0 to 2.2; P = .05) were unchanged, indicating that no bias was introduced by the exclusion of these patients. Similarly, the inclusion of the 32 DRB1-matched patients who either did not receive TB1 or received 1,575 cGy of TB1 did not influence the RR estimate of mortality (RR, 1.4; P = .06 including all patients; RR, 1.4; P = .08 excluding the 32 DRBl-matched patients).
DISCUSSION
Clinical experience has shown that DR molecules are involved in rejection, engraftment, and GVHD.13.20.2' Until now, the role of DR molecules as transplantation determinants has been examined in both marrow2' and solid organ t r a n s p l a n t a t i~n~~~~~ by testing with serologic and cellular techniques that define the broad phenotypes of DR antigens. The results with serologic and cellular techniques suggested that the DRBl gene is important in transplantation, but it has not been possible to type DRBl alleles until recently. With the development of molecular methods, laboratories have made major efforts in redirecting technology and have 
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For Years after Transplant implemented high precision typing of DRB 1 alleles for marrow transplant recipients and donors. In this study, we analyzed the clinical impact of refining donor-recipient matching criteria at the DR locus from matching for DR antigens defined by serology to DRBl alleles detected by molecular methods. Our study shows that molecular techniques can disclose otherwise undetectable DRB 1 mismatching between serologically matched donors and recipients and that DRB 1 allele matching decreases the risk of acute GVHD and improves overall survival. Therefore, the results of unrelated donor marrow transplantation may be improved by better HLA matching for DRBl alleles. Although matching for DRB 1 genes clearly decreased the risk of severe GVHD, the incidence of moderate to severe GVHD in HLA-A, B, DRBl-matched unrelated transplants is still higher than that observed in HLA-matched sibling transplants. In this study, we did not address the potential contribution of other polymorphic class I1 loci such as DRB3, DRBS, DQB 1, or DPBl to account for these findings. Matching for HLA-DQ has been implicated in successful renal tran~plantation.'~ Among unrelated marrow donor-recipient pairs who are matched for the serologically defined private specificites at HLA-A and B and for DRBl alleles, most are matched for other polymorphic loci, including DRB3, DRBS, and DQBl, but are mismatched for DPB 1.' ' Undetected donor/recipient differences may also exist among the highly polymorphic class I genes, HLA-A, B, and C, which lie telomeric to HLA-DR.27,28 The prevalence of disparity for HLA-A, B, C, DRB3, DRBS, and DQBl is likely to be higher among DRBl-mismatched pairs than among DRB1-matched pairs. Thus, it remains difficult to ascertain whether the increased GVHD and decreased sur- 
Years after Transplant
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From vival associated with DRBl disparity in the present study resulted from DRB 1 disparity per se or from the cumulative effects of multiple disparities that were present in association with DRB 1 disparity. The significance of matching for class I, DQB 1, and DPB l alleles in marrow transplant recipients remains to be defined with a larger marrow transplant experience that includes greater numbers of DRB-matched/DQBlmismatched and DRB-, DQB1-, and DPB1-matched transplant pairs. Finally, the role of other gene products encoded within the MHC29,30 and the role of minor (non-MHC) histocompatibility loci3' remain to be determined.
Decreased survival in DRBl-mismatched patients was caused principally by increased transplant-related mortality. In previous analyses, we did not discern a difference in survival between phenotypically (Dw) matched and mismatched transplant recipients." In the present study, we identified DRB 1 mismatches among Dw-matched transplant pairs. With the larger numbers of unrelated transplants evaluated in the present study and the availability of methods to define differences among alleles of the patient and donor, the survival benefit of DRBl matching now becomes apparent.
Previous studies have identified a relationship between HLA mismatching and decreased risk of recurrence of disease, a phenomenon referred to as graft-versus-leukemia eff e~t .~' In the present study, the probability of relapse was the same in both matched and mismatched patients, but this finding should be interpreted cautiously. Previous studies of HLA-identical sibling transplantation have found a significant association of GVHD with a decreased relative risk of Several reasons could explain the apparent absence of a graft-versus-leukemia effect in the present study. Multiple biologic mechanisms may contribute to graft-versus-leukemia effects, and the heterogeneity among the disease diagnoses in our patient population may have precluded the ability to detect any reduction in relapse risk associated with DRB l disparity. Moreover, the small number of patients did not provide the statistical power needed to detect a possible graft-versus-leukemia effect.
The findings reported here raise several important practical issues regarding the approach to and criteria for unrelated donor searches. Although it is clear that more complete and accurate matching for DRB 1 will improve clinical outcome, it will not be possible to find a fully matched donor for all patients. The success in identifying DRBl-matched donors depends on the allele frequency and the specific combination of HLA-A, B, and DRBl alleles inherited by the patient. An unrelated donor search is more likely to be successful if the patient's DRBl alleles are observed frequently in the population or if the patient inherited combinations of HLA-A, B, and DRBl alleles frequently associated with each other. The probability of identifying at least one DRB1-matched donor among those who are confirmed to be HLA-A, B, DR serologically matched with the patient depends on the total number of serologically matched donors identified. 35 In searches that yield a single HLA-A, B, DR serologically matched donor, we have found a 40% chance that the donor and recipient will be DRBl-matched. In searches that yield 5 HLA-A, B, DR serologically matched donors, we have found a 90% chance that at least one will be DRB l-matched.
Increased registry size, broadened racial diversity within registries, and prospective typing of donors for HLA-A, B, and DR may improve the chance of identifying donors for more patients,36 but even with a total registry size of more than 2.4 million donors worldwide, some patients with rare HLA alleles or unusual combinations of alleles will not be able to find an HLA-A, B, DRBl-matched donor. In these cases, the increased time spent in an extended donor search will not serve the best interests of a low-risk patient if the disease progresses before a donor can be identified. For highrisk patients (acute leukemia in resistant relapse or beyond second complete remission and lymphoma), earlier transplantation with a mismatched donor would be preferable to a prolonged search for a fully matched donor, especially in light of findings from this study showing that survival after transplant is strongly influenced by disease stage.
In summary, efforts enabling more patients to receive lifesaving transplants from unrelated donors must include the refinement of HLA donor/recipient matching to reduce transplant-related morbidity and mortality.
This study shows the benefit of matching for DRBl alleles among HLA-A and B identical pairs who are serologically matched for HLA-DR antigens. Prospective matching of DRB 1 genes between potential donors and recipients should be encouraged to provide the best possible chance of success with unrelated transplantation. 
